| Patent application number | Description | Published |
|---|
| 20080249314 | Optical Resolution Method of Amlodipine - The present invention relates to a method for optical resolution of amlodipines by using isopropanol solvent and optically active O,O′-dibenzoyl tartaric acid as chiral reagent. More particularly, the present invention relates to a method comprising (a) obtaining (R)— or (S)-amlodipine dibenzoyl tartrate salt or solvate thereof by reacting (R,S)-amlodipines with optically active O,O′-dibenzoyl tartaric acid in isopropanol solvent, and (b) treating the (R)— or (S)-amlodipine salt with a base, thus obtaining optically active amlodipine. | 10-09-2008 |
| 20080306277 | Process for Preparation of Chiral Amlodipine Gentisate - The present invention relates to a process for the preparation of optically pure amlodipine gentisate, more particularly to a continuous process for the preparation of optically pure amlodipine gentisate with good yield and high optical purity. The processes can be preformed by first reacting racemic (R,S)-amlodipine and optically pure O,O′-dibenzoyltartaric acid in the presence of a solvent including isopropanol to prepare (R)- or (S)-amlodipine dibenzoyltartarate diastereomer or a solvate thereof, treating the prepared amlodipine diastereomeric salt or a solvate thereof with a base and then finally adding gentisic acid. | 12-11-2008 |
| 20090163574 | Stable Pharmaceutical Composition Containing Docetaxel and a Method of Manufacturing the Same - The present invention relates to a stable pharmaceutical composition for injection containing docetaxel and a method of preparing the same. More particularly, the present invention relates to a pharmaceutical composition for injection containing docetaxel having better storage stability than conventional medications, which is prepared by dissolving docetaxel, a water-insoluble compound, in distilled water after mixing it with cyclodextrin (CD) and a water-soluble polymer such as hydroxypropyl methylcellulose (HPMC), polyethylene glycol (PEG) or polyvinylpyrrolidone (PVP) and lyophilizing the mixture, and a method of preparing the same. | 06-25-2009 |
| 20090275755 | Process for the Preparation of S-(+)-Clopidogrel by Optical Resolution - The present invention relates to a process for the preparation of S-(+)-clopidogrel by an optical resolution and, more particularly, to a process for the preparation of S-(+)-clopidogrel represented by the following formula 1 with high optical purity by converting a clopidogrel racemic carboxylic acid into a diastereomeric salt using a (+)-cinchonine for optical resolution, extracting an S-(+)-clopidogrel carboxylic acid from the diastereomeric salt using a suitable solvent under an acidic condition and then reacting the S-(+)-clopidogrel carboxylic acid with methanol. | 11-05-2009 |
| 20100022535 | 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 Inhibitors - 2-pyridyl-substituted imidazoles which are used advantageously in the treatment of diseases mediated by ALK 5 or ALK 4 inhibitors or both. | 01-28-2010 |
| 20100069632 | SALTS OF PYRROLOPYRIMIDINONE DERIVATIVES AND PROCESS FOR PREPARING THE SAME - The present invention relates to salts of a pyrrolopyrimidinone derivative having superior PDE-5 inhibition activity and a process for preparing the same. More particularly, the present invention relates to a crystalline acid addition salt prepared by reacting a pyrrolopyrimidinone derivative with an acid selected from gentisic acid, maleic acid, citric acid, fumaric acid and tartaric acid. With no hygroscopic property and superior long-term storage stability, photostability and thermal stability, the salts of the pyrrolopyrimidinone derivative are appropriate to be prepared into medications and, with superior PDE-5 inhibition activity, are useful for the treatment and prevention of erectile dysfunction, pulmonary arterial hypertension, chronic obstructive pulmonary disease, benign prostatic hypertrophy and lower urinary tract diseases. | 03-18-2010 |
| 20100099773 | INCLUSION COMPLEX OF SIBUTRAMINE AND BETA-CYCLODEXTRIN - The present invention relates to a sibutramine-containing inclusion complex having superior storage stability, and particularly to a pharmaceutically stable inclusion complex suitable for the drug formulation, which prepared by reacting a sibutramine (N,N-dimethyl-1-[1-(4-chlorophenyl)-cyclobutyl]-3-methylbutylamine) of Formula 1 and beta-cyclodextrin in a predetermined ratio, its preparation method and a pharmaceutical composition comprising the same. | 04-22-2010 |
| 20100305202 | LYOPHILIZED PHARMACEUTICAL COMPOSITION WITH IMPROVED STABILITY CONTAINING TAXANE DERIVATIVES, AND METHOD OF MANUFACTURING THE SAME - The present invention relates to a lyophilized pharmaceutical composition for injection having superior storage stability comprising a taxoid, and a method thereof. More specifically, the present invention relates to a lyophilized pharmaceutical composition for injection having improved solubility and stability of dilution compared to the conventional preparations by dissolving a water-insoluble taxoid in distilled water added with a hydrophilic polymer such as hydroxypropylmethyl cellulose (HPMC), polyethylene glycol (PEG) or polyvinylpyrrolidone (PVP) cyclodextrin (CD), and lyophilizing the mixture and a method thereof. | 12-02-2010 |
